Position Overview:

We are building a best‑in‑class Field Medical organization as a natural next step in the growth of our Medical Affairs organization at Beam therapeutics! This Director (or Associate Director) level MSL will own a defined US territory with primary responsibility in sickle cell disease (SCD) and shared accountability across the Beam pipeline, including Alpha‑1 antitrypsin deficiency (Alpha‑1) and glycogen storage disease 1a (GSD). You will architect territory strategy, onboard priority treatment centers, engage KOLs and HCPs, generate actionable insights, and drive pre‑commercial launch readiness in close collaboration with cross‑functional partners.

Responsibilities:

• Develop and execute territory strategy: map treatment centers, referral networks, transplant/infusion sites, cell-collection capabilities, payers, and advocacy groups; prioritize accounts and set measurable objectives.
• Support treatment center onboarding: coordinate scientific and operational readiness aligned with SOPs, compliance, and patient journey requirements; partner with internal teams for qualification and activation.
• Build trusted relationships with KOLs and HCPs: deliver fair-balanced, evidence-based education on rare diseases, cell and gene therapy science, and Beam’s platform; foster advocacy and awareness.
• Educate stakeholders on disease state, therapeutic landscape, and company platform to drive awareness and credibility in the rare disease and CGT space.
• Generate high-quality insights from field interactions: synthesize trends and communicate actionable recommendations to Medical Affairs leadership and cross-functional partners.
• Collaborate on pre-launch planning: align with Medical Strategy, Publications, Medical Information, Value & Evidence, and Medical Operations to ensure scientific messaging, data dissemination, and field tools are ready for first commercial launch.
• Support clinical research activities: identify potential sites, assist with feasibility assessments, and promote best practices for enrollment and retention while maintaining medical/scientific independence.
• Partner cross-functionally with Commercial, Market Access, and Clinical teams while preserving medical independence; coordinate account plans to ensure seamless patient access and avoid duplication.
• Represent the company at congresses and external scientific meetings: plan and execute presence, engage in meaningful scientific exchanges, and follow up to strengthen visibility and credibility.
• Provide education and resources to treatment centers on operational readiness for advanced therapies, including apheresis and cell-handling processes.
• Serve as a trusted resource for compliance and ethical standards: ensure all interactions and materials meet company policies, regulatory requirements, and industry codes.
• Maintain operational excellence: document activities and insights in CRM, monitor KPIs, and continuously improve processes, content, and tools.
• Prepare and deliver training for internal teams and external stakeholders on rare disease management and CGT fundamentals to support launch readiness.
• Act as a scientific ambassador for the company: articulate the value of the platform and pipeline to diverse audiences including clinicians, researchers, and advocacy groups.
• Monitor evolving evidence and competitive landscape in rare disease and CGT; share updates internally to inform strategy and decision-making.

Qualifications:

• Advanced scientific degree (PharmD, PhD, MD, or equivalent).
• ~10+ years industry experience in Medical Affairs with significant Field Medical tenure.
• Rare disease expertise required; hematology strongly preferred with emphasis on SCD.
• Small biotech experience preferred; demonstrated impact in resource‑constrained settings.
• Launch experience (pre‑approval to post‑launch), ideally in CGT or complex specialty (buy‑and‑bill) environments.
• Proven territory management and account planning capability across complex ecosystems (academic centers, community networks, payers, advocacy).
• Independent, proactive operator with strong ownership;
• Cross‑functional collaboration with Clinical, Regulatory, Commercial, Medical Operations, and Publications while maintaining medical/scientific integrity.
• Outstanding communication skills; ability to translate complex science into clear, credible narratives.
• Analytical strength for insight collection, synthesis, and actionable recommendations.
• Travel up to ~60% across assigned territory.
• #LI-Remote

Position Overview:

We are building a best‑in‑class Field Medical organization as a natural next step in the growth of our Medical Affairs organization at Beam therapeutics! This Director (or Associate Director) level MSL will own a defined US territory with primary responsibility in sickle cell disease (SCD) and shared accountability across the Beam pipeline, including Alpha‑1 antitrypsin deficiency (Alpha‑1) and glycogen storage disease 1a (GSD). You will architect territory strategy, onboard priority treatment centers, engage KOLs and HCPs, generate actionable insights, and drive pre‑commercial launch readiness in close collaboration with cross‑functional partners.

Responsibilities:

• Develop and execute territory strategy: map treatment centers, referral networks, transplant/infusion sites, cell-collection capabilities, payers, and advocacy groups; prioritize accounts and set measurable objectives.
• Support treatment center onboarding: coordinate scientific and operational readiness aligned with SOPs, compliance, and patient journey requirements; partner with internal teams for qualification and activation.
• Build trusted relationships with KOLs and HCPs: deliver fair-balanced, evidence-based education on rare diseases, cell and gene therapy science, and Beam’s platform; foster advocacy and awareness.
• Educate stakeholders on disease state, therapeutic landscape, and company platform to drive awareness and credibility in the rare disease and CGT space.
• Generate high-quality insights from field interactions: synthesize trends and communicate actionable recommendations to Medical Affairs leadership and cross-functional partners.
• Collaborate on pre-launch planning: align with Medical Strategy, Publications, Medical Information, Value & Evidence, and Medical Operations to ensure scientific messaging, data dissemination, and field tools are ready for first commercial launch.
• Support clinical research activities: identify potential sites, assist with feasibility assessments, and promote best practices for enrollment and retention while maintaining medical/scientific independence.
• Partner cross-functionally with Commercial, Market Access, and Clinical teams while preserving medical independence; coordinate account plans to ensure seamless patient access and avoid duplication.
• Represent the company at congresses and external scientific meetings: plan and execute presence, engage in meaningful scientific exchanges, and follow up to strengthen visibility and credibility.
• Provide education and resources to treatment centers on operational readiness for advanced therapies, including apheresis and cell-handling processes.
• Serve as a trusted resource for compliance and ethical standards: ensure all interactions and materials meet company policies, regulatory requirements, and industry codes.
• Maintain operational excellence: document activities and insights in CRM, monitor KPIs, and continuously improve processes, content, and tools.
• Prepare and deliver training for internal teams and external stakeholders on rare disease management and CGT fundamentals to support launch readiness.
• Act as a scientific ambassador for the company: articulate the value of the platform and pipeline to diverse audiences including clinicians, researchers, and advocacy groups.
• Monitor evolving evidence and competitive landscape in rare disease and CGT; share updates internally to inform strategy and decision-making.

Qualifications:

• Advanced scientific degree (PharmD, PhD, MD, or equivalent).
• ~10+ years industry experience in Medical Affairs with significant Field Medical tenure.
• Rare disease expertise required; hematology strongly preferred with emphasis on SCD.
• Small biotech experience preferred; demonstrated impact in resource‑constrained settings.
• Launch experience (pre‑approval to post‑launch), ideally in CGT or complex specialty (buy‑and‑bill) environments.
• Proven territory management and account planning capability across complex ecosystems (academic centers, community networks, payers, advocacy).
• Independent, proactive operator with strong ownership;
• Cross‑functional collaboration with Clinical, Regulatory, Commercial, Medical Operations, and Publications while maintaining medical/scientific integrity.
• Outstanding communication skills; ability to translate complex science into clear, credible narratives.
• Analytical strength for insight collection, synthesis, and actionable recommendations.
• Travel up to ~60% across assigned territory.
• #LI-Remote 

Position Overview:

Beam is seeking a dynamic, visionary, and strategic Senior Director, Global HEOR to spearhead the global HEOR strategy for our sickle cell disease program (risto-cel) and other pipeline programs as they emerge . In this high-impact role, the Senior Director, Global HEOR will develop and execute evidence-generation plans, manage stakeholder relationships, and shape external communication strategies. You will partner closely with Clinical Development, Medical Communications and Scientific Publications, Value and Evidence Strategy, Commercial, R&D, and additional cross-functional teams. If you thrive in a collaborative, mission-driven environment and are eager to shape the future of sickle cell disease care, we want you to bring your expertise and passion to Beam.

Responsibilities:

• Provide strategic input to disease prioritization, target product profiles, clinical trial protocols, clinical development plans, and regulatory submissions; lead development of clinical sections for Investigator’s Brochures, briefing books, safety updates, IND/NDA materials, and responses to Health Authority questions. 
• Develop, validate, and integrate patient‑centered outcomes (PROs) into protocols and analyses.
• Interpret clinical trial results (including PROs and healthcare resource use) and partner with Clinical Development/Biostatistics on Statistical Analysis Plans (SAPs) and post‑hoc analyses.
• Lead a fit‑for‑purpose RWE strategy (EHR, claims, registries, hybrid/open datasets) including natural history/registry design and governance to inform endpoints, recruitment, and post‑authorization effectiveness/safety assessments.
• Develop and operationalize external/synthetic control arm approaches (e.g., matched registry cohorts, Bayesian borrowing) for single‑arm or small‑population studies typical in cell & gene therapy.
• Provide operational oversight of Medical Affairs evidence generation, including vendor/CRO governance, milestone/deliverable tracking, data‑quality plans, risk management, and on‑time execution across Medical Affairs–led studies; contribute to long‑term capability building (digital health, real‑world studies).
• Elicit and integrate perspectives from patients, KOLs, policy leaders, and internal stakeholders (market access, marketing, patient advocacy) to ensure plans meet the needs of patients, HCPs, and payers.
• Support Market Access on internal and external payer/policy initiatives (pricing and reimbursement, unmet medical need, regional market dynamics, evidence gaps) across the portfolio.
• Support business decisions around ex-US strategy including, but not limited to, scoping ex-US opportunities, prioritizing country engagement, early scientific advice / parallel consultations with EMA and HTA bodies (e.g., HTACG/JSC), providing advice to development programs on endpoint selection to support product and reimbursement approvals ex-US, etc. 
• Anticipate payer evidence needs and budget‑impact critiques (including preparation for ICER Reviews). 
• Build and maintain economic models (cost‑effectiveness, budget impact) tailored to one‑time CGTs, addressing uncertainty/durability and caregiver burden. 
• Collaborate with Market Access to design innovative payment models and outcomes‑based agreements with pragmatic outcomes and tracking. 
• Lead the AMCP dossier and pre‑approval information exchange (PIE) strategy (6–12 months pre‑launch). 
• Work collaboratively with internal teams, consultants, and CROs to advance development of the portfolio. 

Qualifications:

• Master’s Degree or higher in Health Economics and Outcomes Research or a relevant discipline.
• Formal training in Epidemiology/Health Services Research required.
• At least 10+ years’ experience in observational research study management AND data analytics, either within industry or with an observational research consulting firm.
• Proven track record in drug development, with rare disease experience and an existing network of hematologists preferred.
• Demonstrated ability to lead in a matrixed, cross-functional environment, combining strategic agility with strong business acumen.
• Independent, proactive operator with strong ownership.
• Cross functional collaboration with Clinical, Regulatory, Commercial, Medical Operations, and Publications while maintaining medical/scientific integrity.
• Excellent communication, collaboration, and problem-solving skills.
• #LI-Hybrid